Immutep Limited (IMMP) News

Immutep Limited (IMMP): $2.96

0.04 (+1.37%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

F

Add IMMP to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#204 of 362

in industry

Filter IMMP News Items

IMMP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

IMMP News Highlights

  • IMMP's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for IMMP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • ASX, DEC and III are the most mentioned tickers in articles about IMMP.

Latest IMMP News From Around the Web

Below are the latest news stories about IMMUTEP LTD that investors may wish to consider to help them evaluate IMMP as an investment opportunity.

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Media Release SYDNEY, AUSTRALIA, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a German regulatory authority and part of the Committee for Medicinal Products for Human Use (CHMP), regarding the planned TACTI-004 Phase III trial of e

Yahoo | December 21, 2023

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

Media Release SYDNEY, AUSTRALIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a €1,595,475 (~ A$2,628,354 ) research and development (R&D) tax incentive payment in cash from the French Government under its Crédit d’Impôt Recherche scheme (CIR). The “Crédit d’Impôt Recherche” (CIR), me

Yahoo | December 7, 2023

Immutep (ASX:IMM) investors are sitting on a loss of 22% if they invested five years ago

For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...

Yahoo | November 27, 2023

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

SYDNEY, AUSTRALIA, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the INSIGHT-003 trial has been expanded to four sites across Germany including the University Clinic of Ruhr Universität Bochum and the Lung Clinic Cologne-Merheim. This site expansion will support faster enrolment in this cost-efficient, inv

Yahoo | November 22, 2023

Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Media Release A total of 171 head and neck squamous cell carcinoma (HNSCC) patients enrolled in randomised, multicentre Phase IIb trial evaluating efti in combination with pembrolizumab Efti has FDA Fast Track designation for first-line treatment of HNSCC SYDNEY, AUSTRALIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today a

Yahoo | November 9, 2023

Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

Media Release No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients Good safety profile allows for lead-in phase to be closed early and the randomized Phase II portion of study will now proceed SYDNEY, AUSTRALIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 imm

Yahoo | November 6, 2023

Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer

Media Release Statistically significant increases of Th1 biomarkers (IFN-gamma, CXCL-10), circulating immune cells (lymphocytes), and RNA levels of immune activating genes were observed and linked to improved clinical outcomes Early increase in absolute lymphocyte count is correlated with the positive Overall Survival results in non-small cell lung cancer patients recently reported at ESMO 2023, and is a potential on-treatment biomarker for clinical benefitSimilar immune response biomarkers in t

Yahoo | November 3, 2023

Immutep to Participate in November Investor Events

SYDNEY, AUSTRALIA, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its management will participate in the following upcoming investor events in November: Baird’s Biotech Discovery Series Details:Marc Voigt (CEO), Dr. Frederic Triebel (CSO), Christian Mueller (SVP, Regulatory & Strategy), and Dr. Wade Iams, Assist

Yahoo | November 2, 2023

Immutep Quarterly Activities Report Q1 FY24

Media Release Excellent survival benefit in 1st line non-small cell lung cancer (1L NSCLC) in TACTI-002 trial: median Overall Survival of 35.5 months (TPS ≥1% patients) providing additional 12-18 months survival compared to historical data, reported post periodLate-stage & registrational trial progress: 1st line head & neck squamous cell carcinoma (1L HNSCC) - Phase IIb TACTI-003 trial recruitment progressing and expected to be complete in November 20231L NSCLC - Preparations ongoing to commence

Yahoo | October 31, 2023

Immutep receives ~A$1.13 million R&D Tax Incentive

Media Release (Code: ASX: IMM; NASDAQ: IMMP) SYDNEY, AUSTRALIA, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”), is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program. The cash rebate provided in respect of expenditure incurred on eligible R&D activities conducted in the 2022 fiscal year, mainly related to the Company’s TACTI-002 and TACTI-003 clinical study

Yahoo | October 25, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!